Patient Dies In Pfizer's Long -term Extension Trial Of Hemophilia Drug

Core Viewpoint - Pfizer Inc. is facing scrutiny following the death of a participant in a long-term trial for Marstacimab, a treatment for hemophilia A and B, which raises concerns about the safety of the drug and its ongoing studies [1][3]. Group 1: Trial and Drug Information - The long-term extension trial for Marstacimab involved participants with severe hemophilia A or B, with or without inhibitors, who had previously completed a phase 3 trial (B7841005) [2]. - Marstacimab, marketed as Hympavzi, was approved in the U.S. in October 2022 for treating hemophilia A or B without inhibitors and received European approval in November 2024 [2]. Group 2: Safety and Monitoring - Pfizer, in collaboration with the trial investigator and an independent Data Monitoring Committee, is investigating the circumstances surrounding the participant's death, including pre-existing medical conditions and potential links to the study drug [3]. Group 3: Market Context - Earlier in 2023, Pfizer discontinued its hemophilia B gene therapy product Beqvez due to limited interest, contrasting with Hympavzi, which is a rebalancing agent rather than a gene therapy [4]. - As of the latest trading data, Pfizer's stock is priced at $25.06, reflecting a slight decrease of 0.15% [4].